Anti-viral deal

0

Johnson & Johnson will step deeper into the anti-viral market after the final acquisition agreement of Alios BioPharma, a privately held clinical stage biopharmaceutical company focused on developing therapies for viral diseases. The deal amounts to approx. $1.75 billions. Alios BioPharma’s portfolio includes compound AL-8176, an orally administered antiviral therapy currently in Phase 2 studies for the treatment of infants with respiratory syncytial virus (RSV).

SHARE

LEAVE A REPLY

Please enter your comment!
Please enter your name here